Immunotherapy for Infectious Diseases

Immune Reconstitution with Antiretroviral Chemotherapy 173
19. Holtzer CD, Jacobson MA, Hadley WK, et al. Decline in the rate of specific opportunistic
infections at San Francisco General Hospital (SFGH): 1994–1997 [Letter]. AIDS 1998;
12:1931–1933.
20. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in
patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352:1725–1730.
21. Correll PK, Law MG, McDonald AM, et al. HIV disease progression in Australia in the
time of combination antiretroviral therapies. Med J Aust 1998; 169:469–472.
22. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following
initiation of antiretroviral therapy. JAMA 1998; 279:450–454.
23. Pezzotti P, Dal Maso L, Serraino D, et al. Has the spectrum of AIDS-defining illnesses
been changing since the introduction of new treatments and combination of treatments?
[Letter]. J Acquir Immun Defic Syndr Hum Retroviruses 1999; 20:515–516.
24. Paul S, Gilbert HM, Ziecheck W, et al. The impact of potent antiretroviral therapy on the
characteristics of hospitalized patients with HIV infection. AIDS 1999; 13:415–418.
25. Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomized, placebo-controlled trial of
ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group.
Lancet 1998; 351:543–549.
26. Hirsh M for Protocol 039 (Indinavir) Study Group, Meibohm A, Rawlins S, et al. Indinavir
(IDV) in combination with zidovudine (ZDV) and lamivudine (3TC) in ZDV-experienced
patients with CD4 cell counts � 50 cells/mm 3 . In: Abstracts of the 4th Conference on
Retroviruses and Opportunistic Infections, Washington, DC, 1997 [Abstract #LB7].
27. Baqi M, Kucharczyk W, Walmsley SL. Regression of progressive multifocal leukoencephalopathy
with highly active antiretroviral therapy [Letter]. AIDS 1997; 11:1526–1527.
28. Baldeweg T, Catalan J. Remission of progressive multifocal leukoencephalopathy after
antiretroviral therapy. Lancet 1997; 349:1554–1555.
29. Domingo P, Guardiola JM, Iranzo A, et al. Remission of progressive multifocal leukoencephalopathy
after antiretroviral therapy. Lancet 1997; 349:1554–1555.
30. Elliot B, Aromin I, Gold R, et al. 2.5 year remission of AIDS-associated progressive multifocal
leukoencephalopathy with combined antiretroviral therapy [Letter]. Lancet 1997; 349:850.
31. Power C, Nath A, Aoki FY, Bigio MD. Remission of progressive multifocal leukoencephalopathy
following splenectromy and antiretroviral therapy in a patient with HIV
infection. N Engl J Med 1997; 336:661–662.
32. Cinque P, Casari S, Bertelli D. Progressive multifocal leukoencephalopathy, HIV, and
highly active antiretroviral therapy. N Engl J Med 1998; 339:848–849.
33. Albrecht H, Hoffmann C, Degen O, et al. Highly active antiretroviral therapy significantly
improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy.
AIDS 1998; 12:1149–1154.
34. Carr A, Marriott D, Field A, Vasak E, et al. Treatment of HIV-1-associated microsporidiosis
and cryptosporidiosis with combination antiretroviral therapy. Lancet 1998;
351:256–261.
35. Goguel J, Katlama C, Sarfati C, et al. Remission of AIDS-associated intestinal
microsporidiosis with combined antiretroviral therapy. In: Abstracts of the 37th Interscience
Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, 1997
[Abstr. #I-32].
36. Zingman BS. Resolution of refractory AIDS-related mucosal candidiasis after initiation of
didanosine plus saquinavir. N Engl J Med 1996; 334:1674–1675.
37. Valdez H, Gripshover BM, Salata RA, et al. Resolution of azole-resistant oropharyngeal
candidiasis after initiation of potent combination antiretroviral therapy [Letter]. AIDS
1998; 12:538.
38. Hicks CB, Myers SA, Giner J. Resolution of intractable molluscum contagiosum in a
human immunodeficiency virus infected patient after institution of antiretroviral therapy
with ritonavir. Clin Infect Dis 1997; 24:1023–1025.